DAX19.060 -0,7%ESt504.751 -0,8%MSCIW3.737 ±-0,0%Dow43.269 -0,3%Nas18.987 +1,0%Bitcoin86.804 -0,2%Euro1,0600 ±0,0%Öl73,28 ±-0,0%Gold2.641 +0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Tesla A1CX3T Super Micro Computer A40MRM Bayer BAY001 Palantir A2QA4J MicroStrategy 722713 EVOTEC 566480 Siemens Energy ENER6Y thyssenkrupp 750000 Amazon 906866 Volkswagen (VW) vz. 766403 Coinbase A2QP7J Mercedes-Benz Group (ex Daimler) 710000 RENK RENK73
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet Handel knapp über 19.000 Punkten -- US-Börsen uneinheitlich -- thyssenkrupp: Milliardenverlust -- Rivian-CFO will sich von Millionen Rivian-Aktien trennen -- Super Micro, Xpeng im Fokus
Top News
Icahn Enterprises-Position ausgebaut: In diese Aktien investierte Carl Icahn im 3. Quartal 2024 Icahn Enterprises-Position ausgebaut: In diese Aktien investierte Carl Icahn im 3. Quartal 2024
Kryptorally: Marktkapitalisierung von Ethereum übersteigt die der Bank of America Kryptorally: Marktkapitalisierung von Ethereum übersteigt die der Bank of America
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Ipsen Aktie

NeuKaufenVerkaufen
106,10 EUR +1,30 EUR +1,24 %
STU
107,20 EUR +1,30 EUR +1,23 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.8,80 Mrd. EUR

KGV13,85Div. Rendite1,11%

WKNA0ESMG

ISINFR0010259150

SymbolIPSEF

Ipsen Aktien News

DatumMeistgelesen
GlobeNewswireBylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
GlobeNewswireIqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
GlobeNewswireIpsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Wer­bungIpsen-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswireIpsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
GlobeNewswireIpsen receives its second Shingo Prize for operational excellence
GlobeNewswireIpsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIpsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
GlobeNewswireIpsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
GlobeNewswireFinal results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
GlobeNewswireIpsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
GlobeNewswireIpsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024
GlobeNewswireIpsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024
GlobeNewswireIpsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
GlobeNewswireIpsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
GlobeNewswireIpsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
GlobeNewswireIpsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024
GlobeNewswireIpsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
GlobeNewswireIpsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024
GlobeNewswireHalf-year statement of IPSEN liquidity agreement - 2024 06 30
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024
GlobeNewswireIpsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
BenzingaFDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo
GlobeNewswireIpsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
GlobeNewswireIpsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIpsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   
GlobeNewswireIpsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis    
GlobeNewswireIpsen initiates a share buy-back program to cover its free employee share-allocation plan
GlobeNewswireIpsen announces the launch of an employee shareholding plan
GlobeNewswireAnnual General Meeting of Ipsen S.A. held on 28 May 2024
GlobeNewswireDescription of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024

Ipsen News

Ipsen News: auf dieser Seite finden Sie alle Ipsen News und Nachrichten zur Ipsen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ipsen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ipsen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.